These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 16808005)
1. Mechanism-based inhibition of human liver microsomal cytochrome P450 2D6 (CYP2D6) by alkamides of Piper nigrum. Subehan ; Usia T; Kadota S; Tezuka Y Planta Med; 2006 May; 72(6):527-32. PubMed ID: 16808005 [TBL] [Abstract][Full Text] [Related]
2. Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine. Heydari A; Yeo KR; Lennard MS; Ellis SW; Tucker GT; Rostami-Hodjegan A Drug Metab Dispos; 2004 Nov; 32(11):1213-7. PubMed ID: 15328252 [TBL] [Abstract][Full Text] [Related]
3. Mechanism-based CYP2D6 inactivation by acridone alkaloids of Indonesian medicinal plant Lunasia amara. Takahashi N; Subehan ; Kadota S; Tezuka Y Fitoterapia; 2012 Jun; 83(4):774-9. PubMed ID: 22465502 [TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of the cytochrome P450 isoform by hyperoside and its potent inhibition of CYP2D6. Song M; Hong M; Lee MY; Jee JG; Lee YM; Bae JS; Jeong TC; Lee S Food Chem Toxicol; 2013 Sep; 59():549-53. PubMed ID: 23835282 [TBL] [Abstract][Full Text] [Related]
5. Interaction of terfenadine and its primary metabolites with cytochrome P450 2D6. Jones BC; Hyland R; Ackland M; Tyman CA; Smith DA Drug Metab Dispos; 1998 Sep; 26(9):875-82. PubMed ID: 9733666 [TBL] [Abstract][Full Text] [Related]
7. The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy). Van LM; Heydari A; Yang J; Hargreaves J; Rowland-Yeo K; Lennard MS; Tucker GT; Rostami-Hodjegan A J Psychopharmacol; 2006 Nov; 20(6):834-41. PubMed ID: 16478752 [TBL] [Abstract][Full Text] [Related]
8. Mechanism-based inactivation of cytochrome P450 2D6 by 1-[(2-ethyl-4-methyl-1H-imidazol-5-yl)methyl]- 4-[4-(trifluoromethyl)-2-pyridinyl]piperazine: kinetic characterization and evidence for apoprotein adduction. Hutzler JM; Steenwyk RC; Smith EB; Walker GS; Wienkers LC Chem Res Toxicol; 2004 Feb; 17(2):174-84. PubMed ID: 14967005 [TBL] [Abstract][Full Text] [Related]
9. Selective inhibition of cytochrome P450 2D6 by Sarpogrelate and its active metabolite, M-1, in human liver microsomes. Cho DY; Bae SH; Lee JK; Kim YW; Kim BT; Bae SK Drug Metab Dispos; 2014 Jan; 42(1):33-9. PubMed ID: 24167220 [TBL] [Abstract][Full Text] [Related]
10. The effect of cimetidine on dextromethorphan O-demethylase activity of human liver microsomes and recombinant CYP2D6. Madeira M; Levine M; Chang TK; Mirfazaelian A; Bellward GD Drug Metab Dispos; 2004 Apr; 32(4):460-7. PubMed ID: 16680870 [TBL] [Abstract][Full Text] [Related]
11. Tryptamine: a possible endogenous substrate for CYP2D6. Martínez C; Agúndez JA; Gervasini G; Martín R; Benítez J Pharmacogenetics; 1997 Apr; 7(2):85-93. PubMed ID: 9170145 [TBL] [Abstract][Full Text] [Related]
12. ACAT inhibition of alkamides identified in the fruits of Piper nigrum. Rho MC; Lee SW; Park HR; Choi JH; Kang JY; Kim K; Lee HS; Kim YK Phytochemistry; 2007 Mar; 68(6):899-903. PubMed ID: 17188313 [TBL] [Abstract][Full Text] [Related]
13. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Bertelsen KM; Venkatakrishnan K; Von Moltke LL; Obach RS; Greenblatt DJ Drug Metab Dispos; 2003 Mar; 31(3):289-93. PubMed ID: 12584155 [TBL] [Abstract][Full Text] [Related]
14. Effect of sodium ozagrel on the activity of rat CYP2D6. Wu H; Yu W; Huang L; Wang J; Tang X; Yang W; Liu Y; Yu H; Zhu D Eur J Pharmacol; 2007 Nov; 573(1-3):55-9. PubMed ID: 17651725 [TBL] [Abstract][Full Text] [Related]
15. An in vitro evaluation of cytochrome P450 inhibition and P-glycoprotein interaction with goldenseal, Ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents. Etheridge AS; Black SR; Patel PR; So J; Mathews JM Planta Med; 2007 Jul; 73(8):731-41. PubMed ID: 17611934 [TBL] [Abstract][Full Text] [Related]
16. NADPH-dependent covalent binding of [3H]paroxetine to human liver microsomes and S-9 fractions: identification of an electrophilic quinone metabolite of paroxetine. Zhao SX; Dalvie DK; Kelly JM; Soglia JR; Frederick KS; Smith EB; Obach RS; Kalgutkar AS Chem Res Toxicol; 2007 Nov; 20(11):1649-57. PubMed ID: 17907785 [TBL] [Abstract][Full Text] [Related]
17. Aryl acetylenes as mechanism-based inhibitors of cytochrome P450-dependent monooxygenase enzymes. Foroozesh M; Primrose G; Guo Z; Bell LC; Alworth WL; Guengerich FP Chem Res Toxicol; 1997 Jan; 10(1):91-102. PubMed ID: 9074808 [TBL] [Abstract][Full Text] [Related]
18. Mechanism-based inactivation of CYP2D6 by 5-fluoro-2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]pyrimidine. Palamanda JR; Casciano CN; Norton LA; Clement RP; Favreau LV; Lin C; Nomeir AA Drug Metab Dispos; 2001 Jun; 29(6):863-7. PubMed ID: 11353755 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of human P450 enzymes by natural extracts used in traditional medicine. Rodeiro I; Donato MT; Jimenez N; Garrido G; Molina-Torres J; Menendez R; Castell JV; Gómez-Lechón MJ Phytother Res; 2009 Feb; 23(2):279-82. PubMed ID: 18844254 [TBL] [Abstract][Full Text] [Related]
20. Human cytochrome p450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Chatterjee P; Franklin MR Drug Metab Dispos; 2003 Nov; 31(11):1391-7. PubMed ID: 14570772 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]